TruSight Oncology Comprehensive
Illumina, Inc. · Decision date Aug 14, 2026
What did the FDA approve?
FDA records P230011/S006 as a supplement to PMA P230011, with the supplement type “Panel Track”. The recorded decision is approval, dated Aug 14, 2026.
FDA approval order statement
Approval to expand the intended use of the TruSight Oncology Comprehensive to include a companion diagnostic indication to identify RET fusions in thyroid cancer (TC) patients and RET small DNA variant mutations in medullary thyroid cancer (MTC) patients who may benefit from treatment with RETEVMO (selpercatinib).
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Pathology
- Decision date
- Aug 14, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230011/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Illumina, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Aug 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Illumina, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230011 · Original PMA
TruSight Oncology Comprehensive
P230011/S004 · Related supplement
TruSight Oncology Comprehensive
P230011/S005 · Related supplement
TruSight Oncology Comprehensive
P230011/S006 received
Application receipt date recorded by FDA.
P230011/S007 · Related supplement
TruSight Oncology Comprehensive
P230011/S002 · Related supplement
TruSight Oncology Comprehensive
P230011/S006 · FDA decision
Panel Track
P230011/S008 · Related supplement
TruSight Oncology Comprehensive
Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Illumina, Inc. | PMA approval | Aug 21, 2024 | FDA | |
TruSight Oncology ComprehensiveP230011/S004 | Illumina, Inc. | PMA supplement | Sep 5, 2025 | FDA |
TruSight Oncology ComprehensiveP230011/S005 | Illumina, Inc. | PMA supplement | Sep 19, 2025 | FDA |
TruSight Oncology ComprehensiveP230011/S007 | Illumina, Inc. | PMA supplement | Apr 23, 2026 | FDA |
TruSight Oncology ComprehensiveP230011/S002 | Illumina, Inc. | PMA supplement | Jun 26, 2026 | FDA |
TruSight Oncology ComprehensiveP230011/S008 | Illumina, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Illumina, Inc.
- Headquarters
- Not reported
- Brand website
- illumina.com
- FDA applicant address
- 5200 Illumina Way, San Diego, CA, 92122
Sources and methodology
- Original FDA record: P230011/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






